2025-08-01 - Analysis Report
Okay, here's a report summarizing the provided data for Recursion Pharmaceuticals Inc. (RXRX).

## Recursion Pharmaceuticals Inc. (RXRX) Stock Analysis

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **Accumulated Return (RXRX):** -45.11%
*   **Accumulated Return (VOO):** 38.95%
*   **Absolute Divergence:** -78.7
*   **Relative Divergence:** 7.6

**Analysis:** RXRX has significantly underperformed the S&P 500 over the period examined. The relative divergence of 7.6 indicates that RXRX's performance is near the bottom end of its historical performance range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2021-2023  | 5.0% | 73.6% | -4.0% | 0.0 | 4.3 |
| 2022-2024  | 0.0% | 73.6% | -26.0% | 0.0 | 2.9 |
| 2023-2025  | 6.0% | 73.6% | -42.0% | 0.0 | 2.6 |

**Analysis:**
*   **CAGR:** RXRX's compounded annual growth rate (CAGR) has been variable, with the most recent period showing a 6% increase.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high at 73.6%, indicating substantial risk.
*   **Alpha:** Negative Alpha values suggest underperformance compared to the benchmark. The Alpha has become increasingly negative, showing a growing underperformance.
*   **Beta:** A Beta of 0.0 indicates that the stock's returns are not correlated with the overall market (S&P 500). This could be due to the specific nature of the company's operations and the limited data available.
*   **Cap(B):** The market capitalization has decreased over time, suggesting a decline in investor confidence or company value.

### 2. Recent Stock Price Movement

*   **Current Price:** 5.95
*   **Previous Close:** 5.81
*   **Change:** 2.41%
*   **5-Day Moving Average:** 6.102
*   **20-Day Moving Average:** 5.7907
*   **60-Day Moving Average:** 5.0834

**Analysis:** The stock price closed at 5.95, showing a 2.41% increase from the previous close. The current price is above the 20-day and 60-day moving averages but below the 5-day moving average, indicating a possible short-term pullback after a recent upward trend.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3295 (Low Risk)
*   **RSI:** 62.36
*   **PPO:** -0.4708
*   **Hybrid Signal:** cash_60%_Sell 60.0% of holdings
*   **20-Day Delta Relative Divergence:** 2.5 (+)
*   **Expected Return:** -311.5%

**Analysis:**
*   The MRI is in the low-risk range, suggesting relatively stable market conditions.
*   RSI is at 62.36, indicating the stock is approaching overbought territory.
*   The PPO is slightly negative, suggesting a recent downward trend in price momentum.
*   The Hybrid Signal advises reducing holdings and increasing cash position, likely due to the high volatility and negative long-term outlook.
*   The recent increase in relative divergence (+2.5) suggests short-term positive momentum compared to the S&P 500.
*   The very low Expected Return of -311.5% suggests significant underperformance relative to the S&P 500 if investing over the next 2 years.
*   The price change of 2.41% suggests a notable positive movement, which could be related to recent news or events.

### 4. Recent News & Significant Events

*   **[2025-07-31]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-29]:** Analysts discussing recent performance in the context of industry trends and global economic factors.
*   **[2025-07-28]:** Stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-30]:** Market experts highlighting both risks and opportunities.

**Analysis:** Recent news indicates potential volatility and significant events affecting RXRX. Market analysts are actively discussing the company, pointing to both potential risks and opportunities. Investors should closely monitor company announcements and industry-specific news.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출    |
|------------|-------|---------|
| 2025-05-05 | -0.50 | 0.01 B$ |
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2024-08-08 | -0.40 | 0.01 B$ |
| 2024-05-09 | -0.39 | 0.01 B$ |
| 2025-05-05 | -0.39 | 0.01 B$ |

**Analysis:** RXRX has consistently reported negative Earnings Per Share (EPS). Revenues have been relatively low, with some fluctuations. While there was an increase in revenue in 2024-11-06, the persistent negative EPS indicates that the company is currently not profitable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |
| 2024-03-31 | $0.01B    | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $0.93B    | -21.68%   |
| 2024-12-31 | $1.03B    | -17.29%   |
| 2024-09-30 | $0.52B    | -18.27%   |
| 2024-06-30 | $0.58B    | -16.69%   |
| 2024-03-31 | $0.40B    | -22.78%   |

**Analysis:**
*   **Revenue and Profitability:** While revenue varies each quarter, with a notable spike in Q3 2024, the profit margins are inconsistent. The company showed positive profit margins in Q2 and Q3 2024 but has experienced significant losses in other quarters, including a large loss in Q4 2024.
*   **Capital and Profitability:** The equity has fluctuated, and the Return on Equity (ROE) is consistently negative, indicating that the company is not generating profit from its equity.

### 7. Overall Summary

Recursion Pharmaceuticals Inc. (RXRX) has underperformed the S&P 500 significantly. While it shows potential with its AI-driven approach and recent positive price movement, high volatility, negative earnings, inconsistent profitability, and a negative expected return raise concerns. The hybrid signal advises a reduction in holdings.

**Recommendation:** Caution is advised. Investors should carefully monitor the company's financial performance, news releases, and industry trends before making investment decisions. Further research is needed to assess whether the company can achieve sustainable profitability and positive long-term returns.
